Vericel Corp
NASDAQ:VCEL
Vericel Corp
NASDAQ:VCEL
Price:
49.52 USD
5.5%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
VCEL
stock under the Base Case scenario is
58.03
USD.
Compared to the current market price of 49.52 USD,
Vericel Corp
is
Undervalued by 15%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VCEL
Relative Value
Base Case
58.03
USD
Undervaluation 15%
Valuation Multiples
Multiples Across Competitors
VCEL Competitors Multiples
Vericel Corp Competitors
Vericel Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Vericel Corp
NASDAQ:VCEL
|
2.4B USD | 12 | -744.3 | -1 233.1 | -349.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161.1B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.9B USD | 8.2 | 27.7 | 22.4 | 24.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.7B USD | 10.7 | 29.2 | 23.4 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.5 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.4B USD | 9 | -7.8 | -8.4 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.1T KRW | 18.4 | 74.9 | 45.8 | 63.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
